Das Zentrum
Multiple Sklerose Zentrum Dresden
Patienteninformation
Kontaktinformation
Behandlungsteam
Studienteam
Neuropsychologie
Mobilitätszentrum
Das Mobilitätszentrum
Ganganalyse
Sprunganalyse
DIERS
EMIQ
Forschungsprojekte
Neuroimmunologisches Labor
Das NIL
Neurofilament-Leichtketten Analyse
Autonomes & Neuroendokrinologisches Funktionslabor
Das ANF
Untersuchungsmethoden
MS Living Lab
Management & Science
Team Management & Science
Projekte
eHealth & Analytics
MSDS 3D
MSDS Klinik & Praxis
MS-HRS
MTRS
MS Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
Deutsch
Deutsch
English (UK)
Consensus quality indicators for monitoring multiple sclerosis
MASC
Jahr
Publikationsjahr
2024
Autoren
Autorenliste der Publikation
Voigt I, Fischer S, Proschmann U, Konofalska U, Richter P, Schlieter H, Berger T, Meuth SG, Hartung HP, Akgün K, Ziemssen T.
Verlag
Publisher-Information
The Lancet regional health. Europe, 2024, 40. Jg., S. 100891.
Link
Zur Publikation (externer Server)
https://doi.org/10.1016/j.lanepe.2024.100891
Tags
Forschungsthemen
Multiple Sklerose
MS Behandlung
Management & Science
eHealth
Treatments
MSZ
MASC
eHealth
2024
Change from platform to high efficacy disease-modifying treatment for multiple sclerosis despite NEDA
MS Treatments
Jahr
2024
Rule-Based DSL for Continuous Features and ML Models Selection in Multiple Sclerosis Research
MASC
Jahr
2024
Real-world evidence from Germany and the United States: Treatment initiation on low-efficacy versus high-efficacy therapies in patients with multiple sclerosis
MS Treatments
Jahr
2024
Corticosteroid-depending effects on peripheral immune cell subsets vary according to disease modifying strategies in multiple sclerosis
MS Treatments
Jahr
2024
Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing–Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study
MS Treatments
Jahr
2024
